

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC and AMNEAL  
PHARMACEUTICALS OF NEW YORK, LLC,  
Petitioners,

v.

ALLERGAN, INC.  
Patent Owner

---

CASE: IPR2018-00608  
U.S. Pat. No. 9,161,926

---

**PETITIONERS' EXHIBIT LIST**

*Mail Stop "PATENT BOARD"*  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

<i>Amneal Exhibit #</i>	<i>Description</i>
<b>1001</b>	U.S. Patent No. 9,161,926
<b>1002</b>	Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
<b>1003</b>	<i>Curriculum Vitae</i> for Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
<b>1004</b>	International Patent Application Publication No. WO 2009/061298 (“Garrett”)
<b>1005</b>	International Application Publication No. WO 2010/072958 (“Nadau-Fourcade”)
<b>1006</b>	Certification for Translation of WO 2010/072958
<b>1007</b>	U.S. Patent Publication No. 2006/0204526 (“Lathrop”)
<b>1008</b>	U.S. Patent Publication No. 2010/0029781 (“Morris”)
<b>1009</b>	Osborne, D.W., “Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products,” <i>J. Cosmetic Derm.</i> 10:324-329 (2011) (“Osborne I”)
<b>1010</b>	Aczone® Gel 5% Product Label, approved July 7, 2005 (“Aczone® Gel 5% Label”)
<b>1011</b>	U.S. Patent No. 7,820,186 (“Orsoni”)
<b>1012</b>	Epiduo Product Label, approved December 8, 2008 (“Epiduo Label”)
<b>1013</b>	U.S. Patent Publication No. 2007/0190019 (“Guo”)
<b>1014</b>	Rowe, R.C. et al. (Eds.), Handbook of Pharmaceutical Excipients, 6th Ed., Pharmaceutical Press: London, UK (2009)
<b>1015</b>	Bonacucina, G., <i>et al.</i> , “Characterization and Stability of Emulsion Gels Based on Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer,” <i>AAPS PharmaSciTech</i> 10:368-375 (2009) (“Bonacucina”)
<b>1016</b>	U.S. Patent No. 5,863,560 (“Osborne II”)
<b>1017</b>	U.S. Patent No. 9,161,926 File History
<b>1018</b>	Declaration of Elaine S. Gilmore, M.D., Ph.D.

<i>Amneal Exhibit #</i>	<i>Description</i>
<b>1019</b>	<i>Curriculum Vitae</i> for Elaine S. Gilmore, M.D., Ph.D.
<b>1020</b>	Viscosity of Carbopol® Polymers in Aqueous Systems, published August 13, 2010 (“Lubrizon Technical Data Sheet”)
<b>1021</b>	“Formulating Semisolid Products,” published October 29, 2008 (“Lubrizon Pharmaceutical Bulletin 21”)
<b>1022</b>	Wozel, D., “Innovative Use of Dapsone” <i>Dermatol. Clin.</i> 28: 599–610 (2010) (“Wozel”)
<b>1023</b>	Thiboutot, D., <i>et al.</i> , “Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris” <i>Clin. Pharmacokinet.</i> 46: 697-712 (2007) (“Thiboutot”)
<b>1024</b>	Nguyen, R. and Su, J., “Treatment of Acne Vulgaris” <i>Pediatrics and Child Health</i> 21: 119-125 (2010) (“Nguyen”)
<b>1025</b>	Williams, H., <i>et al.</i> , “Acne vulgaris” <i>Lancet</i> 379: 361–72 (2012) (“Williams”)
<b>1026</b>	Sepineo™ P 600 Brochure
<b>1027</b>	Barclay, L., “Use of Topical Corticosteroids for Dermatologic Conditions Reviewed” <i>Medscape</i> - Jan 21, 2009, accessed from <a href="https://www.medscape.com/viewarticle/587159_print">https://www.medscape.com/viewarticle/587159_print</a> (“Barclay”)
<b>1028</b>	Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins: Baltimore, MD (2005) (“Remington”)
<b>1029</b>	Kim, J-Y., <i>et al.</i> , “Rheological properties and microstructures of Carbopol gel network system,” <i>Colloid. Polym. Sci.</i> 281:614–623(2003) (“Kim”)
<b>1030</b>	Neutralizing Carbopol® and Pemulen® Polymers in Aqueous and Hydroalcoholic Systems, published January 2002 (“Noveon Technical Data Sheet”)
<b>1031</b>	U.S. Patent No. 9,517,219 File History
<b>1032</b>	Piskin, S. <i>et al.</i> “A review of the use of adapalene for the treatment of acne vulgaris,” <i>Therapeutics and Clinical Risk Management</i> 3(4): 621–624 (2007) (“Piskin”)
<b>1033</b>	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Patent and Exclusivity for: N207154


9037812\_1.docx

**CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e), 42.105(a))**

The undersigned hereby certifies that the above-captioned “Petitioners’ Exhibit List” was served in its entirety on February 12, 2018, upon the following parties via FedEx<sup>®</sup>:

Allergan, Inc.  
2525 Dupont Drive, T2-7H  
Irvine, CA 92612-1599

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Date: February 12, 2018

Dennies Varughese (Reg. No. 61,868)  
Lead Counsel for Petitioners

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600